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Moreover, a single dose of polymyxin B administered con-
comitantly with α-amanitin was able to guarantee 100 % 
survival. Polymyxin B protects RNAP II from inactiva-
tion leading to an effective prevention of organ damage and 
increasing survival in α-amanitin-treated animals. The pre-
sent use of clinically relevant concentrations of an already 
human-use-approved drug prompts the use of polymyxin B 
as an antidote for A. phalloides poisoning in humans.
Keywords α-Amanitin · RNA polymerase II · Polymyxin 
B · Liver · Kidney
Introduction
The gathering and consumption of wild mushrooms has 
increased during recent years due to their delicate flavors 
and textures as well as their attributed high nutritional value 
(Cheung 2010). Despite warnings, edible and toxic mush-
rooms such as Amanita phalloides are frequently misidentified 
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by mushroom collectors. This species is responsible for more 
than 90 % of the fatalities caused by mushroom poisoning 
worldwide (Vetter 1998). The high lethality of A. phalloides 
poisoning relies on the presence of powerful toxins such as 
cyclic octapeptides. These cyclic octapeptides are known as 
amatoxins, and α-amanitin is mainly responsible for the severe 
liver and kidney injury observed after A. phalloides poisoning. 
It is well established that α-amanitin inhibits RNA polymerase 
II (RNAP II), thereby interfering with the transcription process 
(Wieland 1983). However, other toxic mechanisms have been 
suggested, namely oxidative stress, which may play a critical 
role (Leist et al. 1997; Zheleva 2013; Zheleva et al. 2007). In 
addition, α-amanitin may also act synergically with endog-
enous cytokines (e.g., tumor necrosis factor-α) to promote 
apoptosis (Leist et al. 1997).
Unfortunately, so far, no consensual antidote for mush-
room poisonings has been found, and therefore, amatoxin poi-
soning is generally associated with a poor outcome, mainly 
due to liver or kidney failure. Several treatments have been 
used after human intoxications with A. phalloides, including 
hormones (e.g., insulin, growth hormone, and glucagon), ster-
oids, vitamin C, vitamin E, cimetidine, α-lipoic acid, antibi-
otics (benzylpenicillin, ceftazidime), N-acetylcysteine, and 
silybin. Of the previous, only benzylpenicillin, ceftazidime, 
N-acetylcysteine, and silybin proved to have some degree of 
therapeutic efficacy, though the death rate remains extremely 
high (Poucheret et al. 2010). The survival of individuals 
depends largely on the severity of liver damage, the rate of 
hepatic regeneration, and the management of complications 
that may develop during the intoxication treatment course 
(Koda-Kimble et al. 2012). Liver transplantation is consid-
ered a last resort; however, it remains the cornerstone of treat-
ment in patients with fulminant hepatic failure (Broussard 
et al. 2001; Pinson et al. 1990).
Considering the main toxicity mechanism of amatoxins 
(i.e., the inhibition of RNAP II activity), the ideal therapeu-
tic approach against A. phalloides intoxications would be 
to displace and/or compete with the amatoxins binding to 
RNAP II without impairing its normal transcription activ-
ity. Therefore, in the present study, we aimed to identify an 
effective antidote for Amanita mushroom poisonings. An 
innovative in silico and in vivo approach based on the bind-
ing of α-amanitin to RNAP II and the screening of clinical 
drugs that show bioisosterism with amatoxins are proposed. 
This bioisosterism was tested in in silico models to assess a 
putative competition and displacement from amatoxins bind-
ing site with RNAP II. After in silico studies, one of the most 
promising candidates, polymyxin B was chosen to proceed 
with in vivo testing, mainly focusing on the target organs 
of α-amanitin toxicity, kidney and liver. Several parameters 
were evaluated, namely the survival rate, histological dam-
age, protein carbonylation, NF-κB nuclear activation, total 
RNA, and specific mRNA quantification, in order to validate 
the effectiveness of polymyxin B in protecting mice against 
α-amanitin poisoning.
Materials and methods
In silico study
Molecular docking on RNAP II
Molecular docking plays an important role in the rational 
design drugs and is helpful in elucidating key features of 
ligand/receptor interactions. This in silico method allows 
predicting the preferred orientation of putative antidotes 
when bound to RNAP II, forming a complex with over-
all minimum energy. Molecular docking studies were 
performed on polymyxin B according to our previous 
reported data (Garcia et al. 2014). The crystal structure of 
RNAP II complexed with α-amanitin (Protein Data Bank 
entry 3CQZ and 2VUM) was used to obtain the start-
ing structures for the molecular docking (Bushnell et al. 
2002), and only subunits Rpb1 and Rpb2 were used. The 
optimized Rpb1 and Rpb2 subunits were docked with 
polymyxin B. The docking procedure was made with the 
AutoDock 4 program (Morris et al. 2009; Mowry et al. 
2013). This automated docking program uses a grid-based 
method for energy calculation of the flexible ligand in 
complex with a rigid protein. The program performs sev-
eral runs in each docking experiment. Each run provides 
one predicted binding mode. The Lamarckian genetic 
algorithm (LGA) was used in all docking calculations. 
The 48 × 44 × 44 grid pointed along the x, y, and z axes 
was centered on the α-amanitin, which was large enough 
to cover all possible rotations of the polymyxin B. The 
distance between two connecting grid points was 0.375 Å. The docking process was performed in 250 LGA runs. 
The population was 150, the maximum number of gen-
erations was 27,000 and the maximum number of energy 
evaluations was 2.5 × 106. After complete execution of 
AutoDock, ten conformations of polymyxin B in com-
plex with the receptor were obtained, which were finally 
ranked on the basis of binding energy. After analysis, the 
best docking solution was chosen as starting structure for 
the subsequent minimization and molecular dynamics 
simulations.
Optimization of polymyxin B
The structure of polymyxin B was constructed and opti-
mized in Gaussian at the HF/6-31G* level of theory. Two 
optimizations were performed: in vacuum and in the con-
densed phase. The partial charges were calculated resorting 
to the RESP method.
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Molecular dynamic (MD) simulations
The enzyme was first neutralized by adding Na+ ions and 
solvated in a cubic box of TIP3P water molecules, such that 
there were at least 10.0 Å of water between the surface of the 
protein and the edge of the simulation box. The initial geome-
try optimization of the enzyme was minimized in two stages. 
In the first stage, only the hydrogen and water atoms were 
minimized; in the second stage, the entire system was mini-
mized. The parameters of the chosen models were validated 
with MD simulations in explicit solvent. The MD was per-
formed with ff99SB force field and the general AMBER force 
field (GAFF) (Case et al. 2005). An initial minimization was 
performed followed by an equilibration of 500 ps. The equi-
libration was performed in a NVT ensemble using Langevin 
dynamics with small restraints on the protein (100 kcal/mol). 
Then, 10 ns of production simulation was performed. This 
represented a substantial computational effort, since each 
system is composed of ≈44,000 atoms containing protein, 
deoxyribonucleic acid (DNA), and ribonucleic acid (RNA). 
Temperature was maintained at 300 K in the NPT ensem-
ble using Langevin dynamics with a collision frequency of 
1.0 ps−1. The time step was set to 2 fs. The trajectories were 
saved every 500 steps for analysis. Constant pressure periodic 
boundary was used with an average pressure of 1 atm. Iso-
tropic position scaling was used to maintain the pressure with 
a relaxation time of 2 ps. SHAKE constraints were applied to 
all bonds involving hydrogen atoms. The particle mesh Ewald 
(PME) method (Essmann et al. 1995) was used to calculate 
electrostatic interactions with a cutoff distance of 8.0 Å.
Calculation of the binding energy
Molecular mechanics with generalized Born and surface 
area solvation (MM-GBSA) was applied to compute the 
binding energy between the RNAP II/polymyxin B com-
plex and to decompose the interaction energies on a per 
residue basis by considering molecular mechanics energies 
and solvation energies (Kollman et al. 2000). The energy 
decomposition was performed for gas-phase energies, des-
olvation free energies calculated by GB model (Onufriev 
et al. 2000), and nonpolar contributions to desolvation 
using the linear combinations of pairwise overlaps (LCPO) 
method (Weiser et al. 1999).
Experimental studies
Chemical and drugs
α-Amanitin, polymyxin B, 1-octanesulfonic acid sodium 
salt, 2,4-dinitrophenylhydrazine, TRIzol, and RNAlater 
were purchased from Sigma-Aldrich (St. Louis, Missouri, 
USA). Methanol and xylene were obtained from Fisher 
Scientific (Waltham, Massachusetts, USA). Sodium chlo-
ride, potassium chloride, sodium hydrogen phosphate, 
potassium dihydrogen phosphate, perchloric acid, Histosec 
paraffin pastilles, magnesium chloride, sodium hydroxide, 
ethylenediaminetetraacetic acid (EDTA), and disodium 
phosphate were purchased from Merck (Darmstadt, Ger-
many). Eosin 1 % aqueous was obtained from Biostain 
(Traralgon, Australia) and Harris hematoxylin from Har-
ris Surgipath (Richmond, Illinois, USA). Water was puri-
fied with a Milli-Q Plus ultrapure water purification system 
(Millipore, Bedford, Massachusetts, USA). Bio-Rad DC 
protein assay kit, Clarity™ Western ECL substrate, iScript 
cDNA Synthesis Kit, and SYBR Green PCR Master Mix 
were purchased from Bio-Rad Laboratories (Hercules, 
California, USA). Horseradish peroxidase-conjugated anti-
rabbit antibody, ECL chemiluminescence reagents, and 
0.45 μm Amersham Protran nitrocellulose blotting mem-
brane were purchased from GE Healthcare Bio-Science 
(Pittsburgh, Pennsylvania, USA). Dinitropenhyl-KLH 
rabbit IgG antibody was purchased from Invitrogen/Life 
Technologies (Grand Island, New York, USA). NF-κB p50 
rabbit polyclonal IgG and goat anti-rabbit IgG F(ab’)2 AP 
conjugated were purchased from Santa Cruz Biotechnology 
(Heidelberg, Germany). All primers were purified through 
high-pressure liquid chromatography and purchased from 
STAB Vida (Caparica, Lisboa, Portugal). The kit for DNase 
digestion step and the ultrapure water was obtained from 
Qiagen (Carnaxide, Portugal).
Animals
Male CD-1 mice (20–30 g) were purchased from Harlan 
(Udine, Italy) and kept in the vivarium of Faculty of Sports, 
University of Porto. Room temperature was maintained at 
22 ± 2 °C, relative humidity at 60 ± 10 %, and a 12-h light/
dark cycle. Water and standard rodent chow 4RF21 GLP 
certificate diet (Mucedola, 113 Settimo Milanese, Italy) 
were provided ad libitum. All procedures were carried out to 
provide appropriate animal care, minimizing their suffering. 
Housing and experimental treatment of the animals were 
in accordance with the guidelines defined by the European 
Council Directive (2010/63/EU) transposed into Portuguese 
law (Decreto-Lei n.o 113/2013, de 7 de Agosto). Moreo-
ver, the experiments were performed with the approval of 
the Ethical Committee of the Faculty of Pharmacy (proto-
col number 10/06/2013), University of Porto. Animals were 
acclimated for 5 days before starting the experiments.
In vivo study design
The murine model has been used as a reliable model for 
α-amanitin poisoning (Schneider et al. 1987, 1992; Tong 
et al. 2007; Yamaura et al. 1986; Zhao et al. 2006), with 
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similar hepatic toxic responses as seen in humans after ama-
toxins administration (Tong et al. 2007). In this model, the 
intraperitoneal (i.p.) administration ensures the bioavailabil-
ity of α-amanitin and it has been the preferred route used in 
previous studies in mice regarding the search for antidotes 
against amatoxin poisoning (Schneider et al. 1987, 1992; 
Tong et al. 2007). In the present work, two in vivo studies 
were performed to evaluate the putative effectiveness of 
polymyxin B against α-amanitin toxicity: a short-term study 
(24 h) and a survival study (30 days). α-Amanitin and pol-
ymyxin B were always dissolved in 0.9 % saline solution. 
In both studies, all α-amanitin-exposed animals received 
an i.p. dose of 0.33 mg/kg. This dose was chosen since 
it was previously reported to be the lethal dose (LD50) of 
α-amanitin in mice (Wieland and Faulstich 1978) and it has 
been used in several studies aiming to test antidotes efficacy 
after amatoxin poisoning (Schneider et al. 1987, 1992; Tong 
et al. 2007; Vogel et al. 1984).
Short‑term study
Our work started with a short-term (24 h) study to evaluate 
the effectiveness of polymyxin B in protecting liver and kid-
ney against the toxicity of α-amanitin. In order to create a 
real scenario of intoxication, since intoxicated people only 
arrive to emergency rooms hours or even days after mush-
rooms ingestion, polymyxin B was only administered to 
animals 4 h post-α-amanitin administration. This 4-h delay 
in the administration was also used in several studies that 
aimed testing the efficacy of other antidotal therapies in mice 
models (Schneider et al. 1992; Tong et al. 2007). Three con-
secutive doses of polymyxin B (2.5 mg/kg) with 4-h inter-
val between each dosage were given to animals. According 
to the allometric scaling standardly used (Beck et al. 2014), 
the three doses of 2.5 mg/kg of polymyxin B in mice sum 
up to approximately 1 mg/kg in a 70-kg human. The current 
recommended dose of intravenous polymyxin B for patients 
with normal renal function is 1.5–2.5 mg/kg/day in two 
doses administered as 1-h infusions (Zavascki et al. 2007). 
Moreover, the three polymyxin B administrations at differ-
ent time-points (4, 8, and 12 h) after α-amanitin injection 
are based on a previous pharmacokinetic study in mice with 
polymyxin B, in which polymyxin B (3 mg/kg) is nondetect-
able in the serum at 4 h post-administration (He et al. 2013).
Animals were randomly divided into four groups that 
were treated as follows: (1) control group, animals sub-
jected to four 0.9 % saline solution i.p. administrations 
(0, 4, 8, and 12 h); (2) α-amanitin group (Ama), animals 
exposed to one dose of α-amanitin (0.33 mg/kg i.p.) fol-
lowed by three 0.9 % saline solution i.p. administrations 
at different time-points (4, 8, and 12 h) post-α-amanitin 
administration; (3) polymyxin B group (Pol), animals 
exposed to a 0.9 % saline solution followed by three 
2.5 mg/kg i.p. administrations of polymyxin B at differ-
ent time-points (4, 8, and 12 h); and (4) α-amanitin plus 
polymyxin B (Ama + Pol), animals exposed to one dose of 
α-amanitin (0.33 mg/kg i.p.) followed by three 2.5 mg/kg 
i.p. administrations of polymyxin B at different time-points 
(4, 8, and 12 h). Twenty-four hours after α-amanitin admin-
istration, all animals were anesthetized with isoflurane and 
killed by exsanguination. The blood, liver, and kidney were 
collected for further analysis.
Survival rate study
Following the promising in silico and short-term in vivo 
studies, the next step was to perform a long-term in vivo 
study, to evaluate survival rate and animals welfare of 
animals intoxicated with α-amanitin and treated with 
polymyxin B. In the α-amanitin group, animal suffering 
was expected; thus, we reduced the number of animals to 
the minimum. Twenty animals were randomly divided 
into five groups that were treated as follows: (1) control 
group, animals treated with 0.9 % saline solution i.p.; (2) 
α-amanitin group (Ama), animals exposed to one dose 
of α-amanitin (0.33 mg/kg i.p.); (3) polymyxin B group 
(Pol), animals treated with 0.9 % saline solution followed 
by 3 × 2.5 mg/kg administrations i.p. of polymyxin B at 
different time-points (4, 8, and 12 h); (4) α-amanitin plus 
polymyxin B group (Ama + Pol conc), animals concomi-
tantly exposed to administration of one dose of α-amanitin 
(0.33 mg/kg i.p.) and polymyxin B (1 × 2.5 mg/kg i.p.); 
and (5) α-amanitin plus polymyxin B group (Ama + Pol), 
animals exposed to α-amanitin (0.33 mg/kg i.p.) followed 
by 3 × 2.5 mg/kg i.p. administrations of polymyxin B at 
different time-points (4, 8, and 12 h). Body weight, motor 
activity, dyspnea, and overall welfare of the animals were 
observed every day, for 30 days.
Short‑term study (24 h) evaluations
Blood collection
In the short-term study, blood was taken from the inferior 
vena cava into EDTA-containing tubes. The blood was imme-
diately centrifuged at 920g for 10 min (4 °C). The plasma 
supernatant was collected into tubes and stored at −80 °C 
until determination of aspartate aminotransferase (AST), ala-
nine aminotransferase (ALT), creatinine, urea, and total bili-
rubin. Plasma biochemical parameters were measured on an 
AutoAnalyzer (PRESTIGE 24i, PZ Cormay S.A.).
Tissue processing for biochemical analysis
After blood collection, liver and kidneys were removed, 
weighed, and processed as follows: (1) Slices of liver and 
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kidney were kept in RNAlater and stored at −80 °C for 
future total RNA quantification and quantitative PCR anal-
ysis; (2) segments of liver and kidney were placed in 4 % 
paraformaldehyde [diluted in phosphate-buffered solution 
(PBS) 1X, 2.5 % sucrose, 0.1 % glutaraldehyde, pH 7.2–
7.4] and used for histological and immunohistochemistry 
analysis; and (3) a section of liver and kidney was placed 
in complete RIPA buffer [50 mM Tris–HCl, 150 mM NaCl, 
1 % Igepal CA-630 (v/v), 0.5 % sodium deoxycholate 
(w/v), and 0.1 % SDS (w/v), pH 7.4, (supplemented with 
0.25 mM PMSF, 1 mM Na3VO4, 10 mM NaF, and 0.5 % 
(v/v) complete protease inhibitor cocktail)] and stored at 
−80 °C for carbonyl quantification.
RNA extraction and real‑time PCR
Total RNA isolation was performed by adding 500 µL 
of TRIzol reagent to liver and kidney samples accord-
ing to the manufacturer’s instructions. All specimens 
were homogenized by mechanical disruption using 
the Ultra-Turrax Mixer (IKAH) instrument, and total 
RNA was extracted in RNase-free environment. A 
DNase digestion step with RNase-free DNase set was 
included, and the total RNA obtained was resuspended 
in ultrapure water. The RNA concentration was deter-
mined by OD260 measurement using a NanoDropH 
ND-1000 Spectrophotometer (NanoDrop Technolo-
gies, USA), and the purity of the total RNA extracted 
was assessed by measuring the absorbance at 230 and 
280 nm. Of total RNA, 200 ng was reverse-transcribed 
using the iScript Select cDNA Synthesis Kit accord-
ing to the manufacturer’s protocol. All cDNA samples 
were stored at −20 °C until quantitative real-time PCR 
(qPCR) analysis. qPCR was performed in iQ™ 5 Real-
Time PCR Detection System (Bio-Rad, Hercules, Cali-
fornia, USA) in 96-well plates with a reaction volume 
of 20 μL and runs up to 40 cycles using iQ™ SYBER® 
Green Supermix. The final PCR mixture of 10 μL con-
tained 0.25 μL of cDNA sample, 5 μL of iQ™ SYBR® 
Green Supermix, 0.25 μL of each primer, and 4.25 μL 
of RNase-free water. The cycling conditions were set as 
follows: Taq DNA polymerase activation at 95 °C for 
3 min; amplification steps: denaturation at 95 °C for 
15 s, annealing at 60 °C for 15 s, and extension at 72 °C 
for 15 s with fluorescence acquisition. Two highly sta-
ble reference genes for RNAP II were chosen (β-actin 
and GAPDH) as well as two ribosomal 18S and 28S 
genes transcribed by RNA polymerase I. All cDNA 
samples were measured in duplicate, and the relative 
transcript levels were quantified by the threshold cycle 
(Ct) value. All primers were designed using the Bea-
con Designer Software (version 7.2, PREMIER Biosoft 
International, Palo Alto, CA, USA).
Histological analysis of liver and kidney
In the short-term study, routine histological procedures for 
qualitative structural analysis of the liver and kidney were 
performed in four mice from each group. The 4 % paraform-
aldehyde-fixed transverse section of the liver and kidney was 
processed for the routine hematoxylin-eosin staining. The 
slides were examined and photographed with a Carl Zeiss 
Imager A1 light microscope equipped with an AxioCam 
MRc 5 digital camera (Oberkochen, Germany). Histopatho-
logical evidences of tissue damage were calculated accord-
ing to their severity and incidence in every slide (Dores-
Sousa et al. 2015). Both liver and kidney, at least 50,000 
cells per slide, were analyzed in a blind fashion in order to 
semiquantify the severity of the following parameters: (1) 
cellular degeneration, (2) interstitial inflammatory cell infil-
tration, (3) necrotic zones, and (4) loss of tissue organization. 
The severity of cellular degeneration was scored according to 
the number of cells showing any alterations (dilatation, vacu-
olization, pyknotic nuclei, and cellular density) in the light 
microscopy visual field: grade 0 = no change from normal; 
grade 1 = a limited number of isolated cells (until 5 % of 
the total cell number); grade 2 = groups of cells (5–30 % of 
cell total number); and grade 3 = diffuse cell damage (30 % 
of total cell number). The severity of necrosis was scored as 
follows: grade 0 = no necrosis; grade 1 = dispersed necrotic 
foci; grade 2 = confluence necrotic areas; grade 3 = mas-
sive necrosis. The inflammatory activity was graded semi-
quantitatively into: grade 0 = no cellular infiltration; grade 
1 = mild leukocyte infiltration (1–3 cells by visual field); 
grade 2 = moderate infiltration (4–6 leukocytes by visual 
field); and grade 3 = heavy infiltration by neutrophils. The 
severity of tissue disorganization was scored according to the 
percentage of the affected tissue: score 0 = normal structure; 
score 1 = less than one-third of tissue; score 2 = greater than 
one-third and less than two-thirds; and score 3 = grater of 
two-thirds of tissue. For each visual field, the highest pos-
sible score was 12 and the lowest was 0.
Determination of NF‑κB through immunohistochemistry
In the short-term study, the determination of NF-κB nuclear 
translocation was performed in both liver and kidney. The 
4 % paraformaldehyde-fixed transverse section of the liver 
and kidney was processed as indicated in section “Histo-
logical analysis of liver and kidney,” and then, the paraffin-
embedded tissues were deparaffinized. The deparaffinized 
tissues were rinsed in distilled water and incubated in PBS 
for 10 min. Thereafter, antigens were unmasked by the micro-
wave antigen-retrieval procedure: slides were immersed in 
10 mM citrate buffer, pH 6.0, at 100 °C and were placed in 
a full-powered microwave for 20 min and then cooled for 
30 min. After washing four times (5 min each) with PBS, 
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the sections were blocked with 3 % bovine serum albumin 
(w/v) in PBS containing 0.05 % Tween 20 (v/v) (PBS-T), for 
30 min to suppress nonspecific binding. Following the block-
ing step, each slide was incubated with anti-NF-κB p50 poly-
clonal rabbit antibody (1:50) in PBS-T overnight (4 °C). After 
washing four times (5 min each) with PBS, the sections were 
incubated for 2 h, at 37 °C with a goat anti-rabbit IgG alka-
line phosphatase secondary antibody (1:100) in PBS-T. The 
sections were then washed four times (5 min) under gentle 
stirring and incubated with fast red reagent for 5 min. After 
washing, the slides were then counterstained with a solution 
of hematoxylin/water (1:5) for 3 min and once again washed. 
Finally, slides were mounted in crystal mount medium with 
coverslips and analyzed by light microscopy. Negative con-
trols were performed as described, with the omission of the 
primary antibody incubation step.
A minimum of 40 cells per area were evaluated, and for 
each section, six areas in each zone were seen. In the liver, 
cell quantification was possible and the number of nuclear 
staining in hepatocytes and macrophage-like cells was 
expressed in number of positive cells per area (μm2).
Protein carbonylation assay
In the short-term study, protein carbonylation, an index of 
protein oxidation, was determined in the liver and in the 
kidneys. Liver and kidney sections were homogenized in 
ice-cold RIPA buffer through sonication. The homogen-
ates were centrifuged at 13,000g, for 10 min, at 4 °C, and 
supernatants were kept at −80 °C until analysis. Samples 
containing 20 µg of protein were then processed as previ-
ously described (Barbosa et al. 2012). Immunoreactive 
bands were detected using the Clarity™ Western ECL Sub-
strate, according to the supplier’s instructions, and digital 
images were acquired using a Molecular Imager® Chemi-
DocTM XRS + System (Bio-Rad Laboratories, California, 
USA) and analyzed with Image Lab™ Software (Bio-Rad 
Laboratories California, USA). Optical density results were 
expressed as % of control values.
Statistical analysis
All data obtained were expressed as mean ± standard devia-
tion (SD). All statistical analysis was performed using 
GraphPad Prism® (version 6.00, GraphPad Software, San 
Diego, California, USA). Comparisons among the survival 
curves were performed using log-rank (Mantel–Cox) test. 
The Shapiro–Wilk test was performed to check normality of 
the data. Statistical comparisons were done using the one-
way ANOVA (in case of normal distribution) followed by 
the Bonferroni post hoc test or Kruskal–Wallis (in case not 
normal distribution) followed by the Dunn’s post hoc test. p 
values <0.05 were considered as statistically significant.
Results
In silico study
Identification of critical residues for polymyxin B binding
A docking study to determine the preferred orienta-
tion of polymyxin B within RNAP II. To gain a broader 
insight of the most important residues for the dynamical 
interactions between these two molecules we performed 
and analyzed 10 ns of MD simulations of the RNAP II/
polymyxin B docked complex. Figure 1 shows superposi-
tion of the average structures of α-amanitin polymyxin B 
during the simulations. The polymyxin B binding site is 
located in the same interface of α-amanitin. In order to 
more easily and accurately grasp the interactions between 
the RNAP II and polymyxin B, an energy decomposition 
analysis of the simulations was also done (Table 1). We 
resorted to the MM-GBSA method, since computational 
studies using MM-GBSA calculations on different com-
plexes of protein/ligands showed good correlations with 
experimental data (Onufriev et al. 2000). Our aim was to 
investigate the interaction features in detail and obtain 
insights into the contribution of each component to the 
RNAP II/polymyxin B binding. The individual energy 
decompositions of all residues in the complex were cal-
culated in order to identify key residues involved in poly-
myxin B binding to RNAP II.
Figure 2 depicts the relative position of the poly-
myxin B and important residues in the binding com-
plex by using the lowest root-mean-square devia-
tion (RMSD) structure with respect to the average of 
the simulation. The polymyxin B interacts with resi-
dues Arg720, Ala1087, Gly1088, Val1089, Val1094, 
Met1285, Ala1357, and Gly1360. The guanidinium 
group of Arg726 forms dipole/dipole interactions with 
L-α-γ-diaminobutyric acid (Dab) residue of poly-
myxin B, which corresponds to energy of −1.97 kcal/
mol. The binding energy of residue Ala1087 backbone 
is −1.41 kcal/mol, thus agreeing with a hydrogen bond 
between Ala1087 oxygen atom and polymyxin B N22 
(Table 2). At the same time, Gly1088 main chain oxy-
gen atom also forms a hydrogen bond with polymyxin 
B N15 (−2.81 kcal/mol) (Table 2). Dipole/dipole inter-
actions were observed between Val1089 and polymyxin 
B (−2.25 kcal/mol). Hydrophobic interactions may be 
the main force between Val1094 and side chain leucine 
residue of polymyxin B, which corresponds to energy of 
−2.25 kcal/mol. Met1285 alkyl group forms CH/π inter-
actions with polymyxin B phenyl group (−1.83 kcal/
mol). Finally, Ala1357 and Gly1360 alkyls groups inter-
act with polymyxin B methyl-octanoic acid group by 
hydrophobic interactions (−0.63 kcal/mol).
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Polymyxin B abolished the increase in plasma 
aminotransferases levels elicited by α‑amanitin
Plasma biomarkers were determined at 24 h after 
α-amanitin administration as shown in Fig. 3. AST and 
ALT were significantly increased in the α-amanitin 
group (359.10 ± 190.40 and 120.20 ± 83.20 U/L for 
AST and ALT, respectively) as compared to control 
group (63.80 ± 8.63 and 37.80 ± 6.94 U/L for AST and 
ALT, respectively). This increase in effect was prevented 
with the 3 × 2.5 mg/kg administration of polymyxin 
B (68.46 ± 23.92 and 32.70 ± 8.45 U/L for AST and 
ALT, respectively) (Fig. 3a, b). On the other hand, urea 
and creatinine show a small tendency to increase in the 
α-amanitin group, however, without reaching statisti-
cal significance (Fig. 3c, d). The ratio AST/ALT and the 
total bilirubin showed no differences between treatments 
(Fig. 3e, f).
α‑Amanitin caused significant decrease in hepatic weight
As an indirect measure of organ damage, we quantified the 
ratio of both liver and kidney weight to total body weight 
in the 24-h study (Table 3). The relative liver weight 
from the α-amanitin group showed a significant decrease 
(5.75 ± 0.58 mg/g) in comparison with control group 
(6.77 ± 0.64 mg/g), and the treatment with polymyxin B 
prevented this effect (5.94 ± 0.52 mg/g) (Table 3). No dif-
ferences were seen in ratios of kidney weight/body weight 
values among control and treatment groups.
Polymyxin B prevented the total RNA decrease in the 
kidney of α‑amanitin‑treated animals
Since α-amanitin rapidly inactivates RNAP II with a con-
sequent decrease in mRNA transcription, we quantified the 
total RNA content in the liver and kidneys of animals in 
Fig. 1  Superposition of RNAP 
II average structure/α-amanitin 
(cyan) and RNAP II aver-
age structure/polymyxin B 
(magenta) (representation of 
α-amanitin is in red and of poly-
myxin B is in yellow) (color 
figure online)
Table 1  Binding energy calculation between the polymyxin B and Rpb1 and Rpb2 subunits (all energies are in kcal/mol)
ΔGele electrostatic energy; ΔGvdw van der Waals energy; ΔGint internal energy; ΔGGas total gas-phase energy (sum ΔGele, ΔGvdw, ΔGint); 
ΔGGBSUR nonpolar contribution to solvation; ΔGGB the electrostatic contribution to the solvation free energy; ΔGGBSOL sum of nonpolar and 
polar contributions to solvation; ΔGGBELE sum of the electrostatic solvation free energy and electrostatic energy; ΔGTOT estimated total binding 
energy
Complex ΔGele ΔGvdw ΔGInt ΔGGas ΔGGBSUR ΔGGB ΔGGBsol ΔGGBele ΔGtot
RNAP II/polymyxin B −62.50 −57.64 0.00 −120.14 −8.45 110.40 101.95 47.90 −18.19
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all experimental groups. These total RNA levels were fur-
ther normalized to organ weight. Results from α-amanitin-
intoxicated animals revealed that the kidney total RNA 
significantly decreased (0.981 ± 0.645 μg/mg kidney) 
compared with control (3.331 ± 0.466 μg/mg kidney) 
(Fig. 4a). This effect was reverted in the α-amanitin plus 
polymyxin B group (3.622 ± 1.550 μg/mg kidney). On the 
other hand, no differences were found for total RNA in the 
liver of α-amanitin-intoxicated animals (Fig. 4b).
Polymyxin B abrogated the α‑amanitin‑induced alteration 
of the transcription process
The evaluation of the genetic transcription by RNAP II was 
based on GAPDH and β-actin mRNA quantitative analysis. 
The relative transcript levels were quantified by the thresh-
old cycle (Ct) value, which increases with a decreasing 
amount of template.
Data from α-amanitin-intoxicated kidney indicated that 
the transcription of GAPDH and β-actin mRNA signifi-
cantly decreased (16.29 ± 1.31 and 17.83 ± 0.36, respec-
tively) when compared to control group (12.98 ± 0.46 
and 14.20 ± 0.3, respectively) (Table 4). This effect 
was reverted in the α-amanitin plus polymyxin B group 
(13.16 ± 0.30 and 15.08 ± 0.68 for GAPDH and β-actin 
mRNA, respectively).
Although the transcript levels of GAPDH mRNA in the 
liver samples of α-amanitin-treated group showed a ten-
dency to decrease (17.28 ± 5.47), it failed to reach statis-
tically significance. Nevertheless, this α-amanitin-treated 
Fig. 2  RNAP II geometries of key residues that produce some favorable interactions with polymyxin B, plotted in the complexes, according to 
the average structure from the MD trajectory
Table 2  Hydrogen bonds 
formed between the polymyxin 
B and RNA polymerase IIa
a Hydrogen bonds were analyzed in the average structures from MD simulation
b The geometric criterion for the formation of H-bonds is common with an acceptor/donor distance <3.5 Å 
and the donor-H-acceptor angle larger than 120°
Toxin/antidote Donor AcceptorH Acceptor Distanceb (Å) Angleb (°)
Polymyxin B Ala1087:O Polymyxin B:2H14 Polymyxin B:N22 2.48 140.27
Gly1088:O Polymyxin B:2H10 Polymyxin B:N15 1.82 168.67
Val1089:N Polymyxin B:2H10 Polymyxin B:N15 2.11 148.55
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tendency was reverted by the treatment with polymyxin B 
(14.80 ± 1.24).
On the other hand, no differences were found for 
β-actin mRNA levels for liver samples (Table 4). Impor-
tantly, RNA polymerase I was not affected by α-amanitin 
poisoning since the transcription of ribosomal proteins 
S18 and S28 by RNA polymerase I was always similar, 
regardless of the organ or experimental group analyzed 
(Table 4).
Fig. 3  Plasma levels of a aspar-
tate aminotransferase (AST), b 
alanine aminotransferase (ALT), 
c urea d creatinine e ratio AST/
ALT and f total bilirubin in con-
trol, 3 × 2.5 mg/kg polymyxin 
B (Pol), 0.33 mg/kg α-amanitin 
(Ama), and α-amanitin plus 
polymyxin B (Ama + Pol) 
groups. Results are presented 
as mean ± standard deviation 
and were obtained from 4 to 5 
animals from each treatment. 
Statistical comparisons were 
made using Kruskal–Wallis 
ANOVA on ranks followed 
by the Dunn’s post hoc test 
(*p < 0.05, Ama vs. control; 
#p < 0.05, Ama vs. Ama + Pol)
Table 3  Ratios of liver weight/body weight and kidney weight/body 
weight
Results are presented as means ± standard deviation from 4 animals 
of each treatment group. Statistical comparisons were made using the 
one-way ANOVA followed by Dunn’s post hoc test (*p < 0.05 vs. 
control)
Control Polymyxin B α-Amanitin α-Amanitin +  
polymyxin B
Liver 6.77 ± 0.64 6.04 ± 0.26 5.75 ± 0.58* 5.94 ± 0.52
Kidney 0.97 ± 0.03 0.85 ± 0.11 0.92 ± 0.09 0.85 ± 0.10
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Polymyxin B prevented α‑amanitin‑induced renal 
and hepatic histological damage
Given the known toxic effects of α-amanitin in the liver 
and kidneys, we proceeded to a histopathological anal-
ysis to evaluate the putative protective tissue effects of 
the polymyxin B antidote. As expected, liver samples 
from the control and polymyxin B groups presented a 
normal structure at light microscopy, without evidences 
of edema, necrosis, or cellular infiltrations (Fig. 5b; 
Table 5). On the other hand, α-amanitin caused promi-
nent hepatic cellular edema, cytoplasmic vacuolization, 
and interstitial inflammatory cell infiltration (Fig. 5c; 
Table 5). Moreover, the α-amanitin group showed some 
necrotic foci in the liver (Fig. 5c; Table 5), which were 
more evident in the centrilobular zone. The group of 
α-amanitin plus polymyxin B showed a significant 
decrease in α-amanitin-induced necrosis, edema, and 
cytoplasmic vacuolization (Fig. 5d; Table 5). However, 
polymyxin B was not able to prevent the α-amanitin-
induced increase in interstitial infiltration of inflamma-
tory cells (Fig. 5d; Table 5).
Regarding the kidney, control and polymyxin B 
groups presented a normal renal structure at light 
microscopy (Fig. 6a, b; Table 5). Histological exami-
nation of α-amanitin-treated kidney (Fig. 6c; Table 5) 
revealed severe degenerative changes: (1) The renal 
corpuscles appear heterogeneous, with a wide capsu-
lar space, and thickened external Bowman capsule; 
(2) proximal tubules showed necrotic cells vacuoliza-
tion and edema; and (3) distal tubules cells had signs 
of atrophy and degeneration, while a large amount 
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Fig. 4  a Total RNA liver levels and b total RNA kidney levels of 
control, 3 × 2.5 mg/kg polymyxin B (Pol), 0.33 mg/kg α-amanitin 
(Ama), and α-amanitin plus polymyxin B (Ama + Pol) groups. 
Results were obtained from four animals from each treatment group. 
Statistical comparisons were made by one-way ANOVA, followed by 
the Bonferroni post hoc test, (*p < 0.05, Ama vs. control; #p < 0.05, 
Ama vs. Ama + Pol)
Table 4  Relative mRNA 
levels of S28, S18, GAPDH, 
and β-actin genes in liver and 
kidney samples
Results are presented as mean ± standard deviation of threshold cycles from 4 animals from each treat-
ment group. Statistical comparisons were made using ANOVA followed by Bonferroni post hoc test 
(****p < 0.0001, Ama and vs. Control; ####p < 0.0001, Ama and vs. Ama + Pol)
RNAP I RNAP II
S18 S28 GAPDH β-Actin
Liver
Control 14.75 ± 1.41 17.27 ± 0.68 14.55 ± 1.46 17.44 ± 2.47
Polymyxin B 14.60 ± 1.82 17.95 ± 1.51 14.75 ± 1.41 17.31 ± 1.59
α-Amanitin 13.68 ± 0.61 16.87 ± 0.36 17.28 ± 5.47 16.10 ± 1.77
α-Amanitin + polymyxin B 13.97 ± 0.46 17.52 ± 0.42 14.80 ± 1.24 16.47 ± 1.33
Kidney
Control 14.09 ± 0.83 17.06 ± 0.82 12.98 ± 0.46 14.20 ± 0.37
Polymyxin B 13.84 ± 0.35 16.84 ± 0.42 12.49 ± 0.38 14.89 ± 0.44
α-Amanitin 13.95 ± 1.72 17.37 ± 1.36 16.29 ± 1.31**** 17.83 ± 0.36****
α-Amanitin+
polymyxin B
13.55 ± 0.89 16.82 ± 0.69 13.16 ± 0.30#### 15.08 ± 0.68####
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of a protein-related material caused enlargement and 
obstruction of these tubules (Fig. 6c). Noteworthy, in the 
α-amanitin plus polymyxin group, the damage induced 
by α-amanitin was significantly attenuated, particularly 
regarding the necrotic foci and the obstruction of distal 
tubules (Fig. 6d; Table 5).
Fig. 5  Liver histology: a light micrograph from the control group 
showing normal morphology and structure; b light micrograph from 
the polymyxin B group showing normal morphology and structure; 
c light micrograph from α-amanitin group. The presence of cellu-
lar edema (yellow arrow), cytoplasmic vacuolization (white arrow), 
inflammatory cells (green arrows), as well as some necrotic zones 
can be seen (cyan arrows); d light micrograph from α-amanitin plus 
polymyxin B group. The edema and cytoplasmic vacuolization and 
necrosis were significantly attenuated by polymyxin B (color figure 
online)
Table 5  Semiquantitative 
analysis of the morphological 
injury parameters of control, 
α-amanitin, and α-amanitin plus 
polymyxin B groups
Results of hematoxylin-eosin staining, given in scores, are presented as means ± standard deviation from 
4 animals from each treatment group. Statistical comparisons were made using Kruskal-Wallis ANOVA 
on Ranks followed by the Dunn’s post hoc test (*p < 0.05, ****p < 0.0001, treatment vs. control; 
####p < 0.0001, Ama group vs Ama + Pol)
Control Polymyxin B α-Amanitin α-Amanitin + polymyxin B
Liver
 Cellular degeneration 0.00 ± 0.00 0.25 ± 0.44 2.02 ± 0.42**** 0.44 ± 0.50* ####
 Necrosis 0.00 ± 0.00 0.16 ± 0.49 1.62 ± 0.49**** 0.42 ± 0.50* ####
 Inflammatory activity 0.25 ± 0.43 0.23 ± 0.42 2.09 ± 0.35**** 2.04 ± 0.20****
Kidney
 Cellular degeneration 0.27 ± 0.45 0.20 ± 0.41 2.26 ± 0.44**** 1.08 ± 0.33****####
 Necrosis 0.00 ± 0.00 0.00 ± 0.00 2.06 ± 0.62**** 0.61 ± 0.55****####
 Inflammatory activity 0.22 ± 0.42 0.19 ± 0.40 1.81 ± 0.42**** 1.66 ± 0.48****
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α‑Amanitin caused NF‑κB nuclear translocation that was 
not reverted by polymyxin B
The translocation of the NF-κB factor to the nuclei was 
assessed by immunohistochemistry in the liver and kid-
ney (Figs. 7, 8) in the short-term study. The liver of con-
trol and polymyxin B groups showed mainly cytoplasmic 
staining without marked nuclear staining cells (Fig. 7a, b). 
On the other hand, α-amanitin caused significant nuclear 
translocation of NF-κB mainly in the macrophage-like cells 
(0.0397 ± 0.0168 cells/μm2) when compared to control 
group (0.0018 ± 0.0027 cells/μm2) (Fig. 7c, e). Moreover, 
α-amanitin was also able to cause a significant increase in 
hepatocytes staining positive as a result of activated nuclear 
NF-κB (0.0151 ± 0.0093 cells/μm2) (Fig. 7c, f) when com-
pared to the control group (0.0012 ± 0.0049 cells/μm2). 
The α-amanitin plus polymyxin B group (0.0048 ± 0.0319 
and 0.0019 ± 0.0129 cells/μm2 for macrophage-like cells 
and hepatocytes, respectively) showed similar results to 
α-amanitin group; therefore, polymyxin B was not able to 
revert the pro-inflammatory effects of α-amanitin (Fig. 7d–f).
Regarding the kidneys, the results showed predominant 
cytoplasmic staining in control and polymyxin B groups 
(Fig. 8a, b), whereas in both α-amanitin and α-amanitin 
plus polymyxin B groups an increase in macrophage-like 
cells staining positive for activated NF-κB was observed 
(Fig. 8c, d). Due to the heterogeneity of the tissue, the 
accurate nuclear staining count of the type of cell marked 
was difficult; therefore, only the representative light micro-
graphs of the kidney (Fig. 8) are presented.
Polymyxin B prevented the α‑amanitin increase in hepatic 
protein carbonylation
Protein carbonylation is an indicator of severe oxidative dam-
age, which often leads to a loss of protein function. As shown 
Fig. 6  Kidney histopathology: a light micrograph from the control 
group showing normal morphology and structure; b light micrograph 
from the polymyxin B group showing normal morphology and struc-
ture; c light micrograph from α-amanitin group. The presence of cel-
lular edema (yellow arrow), cytoplasmic vacuolization (green arrow), 
and large amounts of protein-related material cause enlargement and 
obstruction of distal tubules (white arrow), and some necrotic zones 
can be seen (cyan arrow); d light micrograph from α-amanitin plus 
polymyxin B group. The obstruction of distal tubules, edema, cyto-
plasmic vacuolization, and necrosis were significantly attenuated 
after polymyxin B (color figure online)
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Fig. 7  Immunohistochemistry of NF-κB activation in the liver by 
light microscopy: a light micrograph from the control group show-
ing only cytoplasmic staining without marked nuclear staining 
cells; b light micrograph from polymyxin B group showing only 
cytoplasmic staining without marked nuclear staining cells; c light 
micrograph from α-amanitin group showing a higher number of 
cell staining positive for activated NF-κB in the macrophage-like 
cells (yellow arrows) and in the hepatocytes (cyan arrows). d Light 
micrograph from α-amanitin plus polymyxin B group showing a 
higher number of cells staining positive for activated NF-κB in the 
macrophage-like cells (yellow arrow). e Number of macrophage-
like cells staining positive for activated NF-κB. f Number of hepato-
cytes staining positive for activated NF-κB of control, 3 × 2.5 mg/kg 
polymyxin B (Pol), 0.33 mg/kg α-amanitin (Ama), and α-amanitin 
plus polymyxin B (Ama + Pol) groups. Results were expressed as 
mean ± standard deviation. Results were obtained from four animals 
from each treatment group. Statistical comparisons were made using 
Kruskal–Wallis ANOVA on ranks followed by the Dunn’s post hoc 
test (****p < 0.0001, Ama and Ama + Pol vs. control) (color figure 
online)
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in Fig. 9a, liver protein carbonylation increased significantly in 
α-amanitin group (127.6 ± 7.1 %) when compared to control 
group (100.0 ± 10.1 %). Treatment with polymyxin B signifi-
cantly attenuated hepatic α-amanitin-induced increase in pro-
tein carbonylation (107.8 ± 16.1 %). In the kidneys, although 
a tendency to increase was observed in the α-amanitin group 
(122.9 ± 34.3 %), when compared to control (100.0 ± 13.3 %), 
no statistical significance was reached (Fig. 9b).
Survival rate and welfare examination
A long-term survival study (30 days) was done with two differ-
ent polymyxin B treatment regimens after α-amanitin (0.33 mg/
kg i.p.): (1) Polymyxin B was administered at 4, 8, and 12 h 
(3 × 2.5 mg/kg i.p.), and (2) polymyxin B (1 × 2.5 mg/kg) was 
concomitantly administered with α-amanitin.
All mice exposed to 0.33 mg/kg of α-amanitin 
died within 5 days (Fig. 10). All deaths occurred 
within 2–5 days α-amanitin post-administration. 
α-Amanitin-treated animals became hunched and lethar-
gic soon after dosing. Subsequently, mice showed apathy, 
reduced mobility, respiratory problems, seizures, and diso-
rientation until they died within 24 h of these symptoms 
arousal.
The concomitant administration of α-amanitin and pol-
ymyxin B resulted in 100 % of survival. The group that 
received concomitant administration of polymyxin B with 
α-amanitin showed moderate signs of discomfort at day 
five, namely involuntary movements of the head that per-
sisted without improvement until the end of the experiment.
In the group that received multiple doses of polymyxin 
B and α-amanitin, a 50 % survival rate was observed. All 
deaths occurred within 5–7 days. In the surviving ani-
mals that received multiple doses of polymyxin B and 
α-amanitin, no poisoning signs were observed.
Neither the polymyxin B group (3 × 2.5 mg/kg i.p.) nor 
the control group showed any other signs of discomfort 
during the 30-day experiment.
Fig. 8  Immunohistochemistry of NF-κB activation in the kidney by 
light microscopy. a Light micrograph from the control group show-
ing only cytoplasmic staining without marked nuclear staining cells. 
b Light micrograph from polymyxin B group showing only cytoplas-
mic staining without marked nuclear staining cells. c Light micro-
graph from α-amanitin group showing cell staining positive for acti-
vated NF-κB in the macrophage-like cells (yellow arrow). d Light 
micrograph from α-amanitin plus polymyxin B group showing cell 
staining positive for activated NF-κB in the macrophage-like cells 
(yellow arrow) (color figure online)
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Discussion
The present work reports the discovery of what we believe 
will be the first effective antidote for A. phalloides poison-
ing: polymyxin B. The present study provides unequivo-
cal in silico and in vivo evidence that polymyxin B gives 
a potent protection against α-amanitin-induced toxicity, by 
interfering with its main mechanism of toxicity, the inhibi-
tion of RNAP II activity. Outstandingly, the in silico studies 
on RNAP II were shown to be of outmost importance in 
the development process, and the successful in vivo stud-
ies allow the suggestion of immediate use of the antidote in 
addition to the current therapeutic measures, as polymyxin 
B is a therapeutic drug with a well-established clinical use.
We started with the application of in silico methods, tak-
ing advantage of the description of the crystal structure of 
α-amanitin with yeast RNAP II that revealed several key 
molecular interactions that may contribute to the inhibi-
tion of RNAP II activity (Bushnell et al. 2002). Based on 
that structure, we have recently reported an in silico study 
in which we provided new insights into the inhibition 
mechanism of RNAP II by α-amanitin; additionally, the 
mode of interaction of α-amanitin and three clinically used 
antidotes (benzylpenicillin, ceftazidime, and silybin) with 
Fig. 9  a Protein carbonylation levels in the liver; b protein carbon-
ylation levels in the kidney, control, 3 × 2.5 mg/kg polymyxin B 
(Pol), 0.33 mg/kg α-amanitin (Ama), and α-amanitin plus polymyxin 
B (Ama + Pol) groups. Results were expressed as percentage varia-
tion of control values and expressed as mean ± standard deviation. 
Results were obtained from four animals from each treatment group. 
Statistical comparisons were made by one-way ANOVA, followed by 
the Dunn’s post hoc test, (*p < 0.05, Ama vs. control; #p < 0.05, Ama 
vs. Ama + Pol)
Fig. 10  Survival rate curves after concomitant i.p. administration of 
0.33 mg/kg of α-amanitin and polymyxin B (2.5 mg/kg) and adminis-
tration of polymyxin B (2.5 mg/kg) 4, 8, and 12 h after initial admin-
istration of α-amanitin. Results are expressed as percent survival. 
Results were obtained from four animals in each treatment. Statistical 
comparisons were made using log-rank (Mantel–Cox) test (*p < 0.05, 
Ama + Pol 2.5 mg/kg vs. Ama; **p < 0.01, Ama + Pol 2.5 mg/kg vs. 
Ama; ##p < 0.01, Ama vs. control). Blue line represents saline con-
trol treatment, dark purple represents polymyxin B treatment; violet 
line represents the treatment with α-amanitin, yellow line represents 
the concomitant treatment with α-amanitin and polymyxin B (2.5 mg/
kg), and magenta line represents the administration of polymyxin B 
(3 × 2.5 mg/kg) 4, 8, and 12 h after α-amanitin (color figure online)
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RNAP II, using docking methods and molecular dynamics 
simulations, was investigated (Garcia et al. 2014). Multi-
ple relevant interactions between α-amanitin and RNAP II 
are located in the bridge helix and the trigger loop. Thus, 
α-amanitin may block RNAP II translocation by interact-
ing with the bridge helix, preventing the conformational 
change in the trigger loop and consequent transcriptional 
elongation. Benzylpenicillin, ceftazidime, and silybin were 
shown able to bind to the same site as α-amanitin, although 
not replicating the unique α-amanitin binding mode. These 
drugs establish considerably less intermolecular interac-
tions than α-amanitin, and the ones that exist are essentially 
confined to the bridge helix and adjacent residues (Garcia 
et al. 2014). These results show that the therapeutic effect 
of these drugs does not seem to be directly related to the 
binding with RNAP II but to other mechanisms. Therefore, 
an antidote that regenerates the RNAP II or that prevents 
the α-amanitin binding to RNAP II does not yet exist and 
clinical efficacy of the treatments after A. phalloides is still 
low (Garcia et al. 2015a).
Herein, we have applied the same in silico methodol-
ogy to a peptide with similar composition and molecu-
lar weight of amatoxins, polymyxin B, and confirmed 
its ability to displace α-amanitin from RNAP II. Poly-
myxin B was never tested as an antidote for α-amanitin. 
Docking and MD simulations were carried out to study 
the mode of interaction of RNAP II/polymyxin B com-
plex using binding energy decomposition based on the 
MM-GBSA approach, as reported before for other mol-
ecules (Garcia et al. 2014). Three valuable findings could 
be observed in silico: (1) polymyxin B binding site is 
located in the same interface of α-amanitin, which can 
prevent the binding of the toxin; (2) polymyxin B does 
not interact with bridge helix residues allowing the tran-
scription process; and (3) hydrogen bond, CH/π, and 
hydrophobic interactions drive the bonds between poly-
myxin B and RNAP II. Therefore, the polymyxin B bind-
ing location on RNAP II can potentially protect RNAP II 
from the α-amanitin-induced impairment. In fact, compe-
tition between polymyxin B and α-amanitin and/or dis-
placement of α-amanitin from RNAP II by polymyxin 
can occur depending on the affinity of each molecule for 
the RNAP II binding site.
To prove the applicability of our in silico results, we 
used an in vivo model often applied to study α-amanitin 
toxicity (Schneider et al. 1987, 1992; Tong et al. 2007; 
Yamaura et al. 1986; Zhao et al. 2006). Since RNAP 
II is considered the main target for α-amanitin toxic-
ity, mRNA levels can be used as a measure of its inhibi-
tion (Larson 2011), and our results showed that inhibition 
of renal GAPDH and β-actin mRNA transcription elic-
ited by α-amanitin was efficiently reverted by polymyxin 
B. Still, in the liver, changes in mRNA levels of GAPDH 
and β-actin did not reach significance. This apparent dis-
crepancy between the liver and kidney could be explained, 
at least partially, by the process of mRNA turnover. The 
turnover of mRNA is complex and organ/cell specific, and 
the several critical mechanisms are not yet fully understood 
(Beelman and Parker 1995; Guhaniyogi and Brewer 2001; 
Ross 1995). Moreover, the mRNA half-life varies greatly 
between different cell types. In rat hepatocytes, the half-life 
for β-actin mRNA is 9 h (Reuner et al. 1995), whereas in 
HepG2 cells it is reported as 5–6 h (Gao et al. 2003). In 
addition, a half-life of 6.6 and 13.5 h in human leukemia 
Nalm-6 (B cell derived) and CCRF-CEM (T cell derived) 
cells, respectively, was reported for the same mRNA tran-
script (Leclerc et al. 2002). Furthermore, the regulation of 
mRNA stability is likely to be an essential component in 
the tissue response to toxins exposure, and it differs among 
organs (Ross 1995). To the best of our knowledge, in CD-1 
mice, the half-lives of hepatic or renal GAPDH and β-actin 
mRNA are not presently known. Moreover, in the present 
study, GAPDH seemed to be a more sensitive marker for 
α-amanitin intoxication at 24 h in the kidney. However, 
organ differences of α-amanitin accumulation may also 
have an important influence in the observed results, as we 
have previously reported (Garcia et al. 2015b).
Polymyxin B not only had a strong impact on genetic 
expression, but also caused a clear protection against 
α-amanitin-induced injury. Serum aminotransferases (ALT 
and AST) have been used as sensitive indicators for liver 
injury caused by amatoxins (Chang and Yamaura 1993; 
Yamaura et al. 1986; Zhao et al. 2006) and, in accordance, 
in our model, AST and ALT were significantly increased in 
the α-amanitin-intoxicated group. That α-amanitin-induced 
increase was totally reverted by administration of multiple 
doses of 2.5 mg/kg polymyxin B. Moreover, the plasma 
findings were corroborated by histological observations. 
The liver of mice administered with α-amanitin evidenced 
severe damage, with cellular edema, cytoplasmic vacu-
olization, and interstitial inflammatory cell infiltration, as 
well as some centrilobular necrotic zones. These histologi-
cal phenotypes are in agreement with previous reports of 
α-amanitin studies in mice (Kaya et al. 2014; Wills et al. 
2005; Zhao et al. 2006). α-Amanitin (1 mg/kg i.p.)-treated 
Balb/c mice showed vacuolar degeneration of liver cells, 
1 and 6 h after poisoning (Kaya et al. 2014), whereas 
α-amanitin (0.327 mg/kg intravenous) caused liver fatty 
degeneration and necrosis 48 h after treatment in the same 
mice strain (Zhao et al. 2006). Moreover, histopathologi-
cal hepatic damage in laboratory animals is similar to that 
found in humans after A. phalloides intoxication, namely 
regarding features of hepatic massive centrilobular necrosis 
and vacuolar degeneration (Fineschi et al. 1996).
Regarding the kidney, although less studied in humans, 
it is also a target organ for A. phalloides poisoning. Human 
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data indicate that acute tubular necrosis with kidney fail-
ure occurs in amatoxins-intoxicated patients (Mydlik and 
Derzsiova 2006). In animal models, intense tubular necro-
sis was described in Balb/c mice 48 h after α-amanitin 
(0.327 mg/kg intravenous) (Zhao et al. 2006). In our work, 
the histological examination of α-amanitin-intoxicated 
kidney revealed extensive damage and a significant intra-
tubular obstruction. Although the nature of that obstruc-
tion is unknown, the reduced tubular epithelial cell pro-
liferation as a consequence of inhibition of RNAP II and 
cellular necrosis may lead to that material accumulation. 
Noteworthy, the administration of polymyxin B protected 
against the occurrence of the majority of the renal dam-
age inflicted by α-amanitin, namely cellular edema, cyto-
plasmic vacuolization, and necrosis. However, polymyxin 
B was not able to revert the hepatic and renal pro-inflam-
matory effect that occurred after α-amanitin. Indeed, in the 
present work, NF-κB was strongly activated in the liver 
and kidney exposed to α-amanitin, whereas polymyxin 
was not able to revert that NF-κB nuclear translocation. 
The nuclear factor NF-κB pathway has been considered a 
prototypical pro-inflammatory signaling pathway, based 
on the role of NF-κB in the expression of pro-inflamma-
tory genes including cytokines, chemokines, and adhesion 
molecules (Lawrence 2009). To the best of our knowl-
edge, this was the first time that NF-κB factor was shown 
to play a role on α-amanitin toxicity. Moreover, NF-κB 
activation can promote liver injury through the genetic 
transcription of TNF-α and IL-6 (Murr et al. 2002; Zhang 
et al. 2007; Zhao et al. 2005). In fact, TNF-α has been 
implicated in α-amanitin-induced hepatotoxicity in vivo, 
since after α-amanitin (3 mg/kg i.p.), the levels of hepatic 
TNF messenger RNA were shown to increase, concurring 
to hepatocytes apoptosis (Leist et al. 1997). Consistently, 
mice deficient of the 55-kDa TNF receptor were protected 
from α-amanitin-induced toxicity (Leist et al. 1997). The 
authors suggested that the synergism between TNF-α and 
α-amanitin may explain the highly hepatotoxic potential 
of α-amanitin in vivo (Leist et al. 1997). In the present 
work, it is reasonable to assume that the pro-inflammatory 
effect of NF-κB may be responsible for some of the late 
deaths on the survival study when polymyxin B was only 
administered 4 h after α-amanitin. On the other hand, when 
administered concomitantly, polymyxin B possibly pre-
vented α-amanitin to reach RNAP II, thereby avoiding any 
significant side effect. The link between α-amanitin RNAP 
II inhibition and NF-κB activation should be further inves-
tigated as it could establish other pathways for antidotal 
therapy against this toxin.
α-Amanitin toxicity has been associated with oxida-
tive stress, and protein carbonylation is seen as a sta-
ble biomarker of oxidative stress as protein turnover can 
take hours or days (Dalle-Donne et al. 2003). Herein, 
protein carbonylation increased significantly in liver of 
mice exposed to α-amanitin, relatively to the control group, 
suggesting that α-amanitin is able to alter protein redox sta-
tus. This effect was abrogated by the multiple administra-
tion of polymyxin B. Available data regarding α-amanitin 
ability to induce oxidative stress are elusive. Mice treated 
with α-amanitin (1 mg/kg i.p.) and killed 20 h after poi-
soning showed liver superoxide dismutase activity increase 
(Zheleva et al. 2007). The authors concluded that in vivo 
α-amanitin liver accumulation could lead to reactive oxy-
gen species (ROS) formation, in particular superoxide 
anion radical (Zheleva et al. 2007). Recently, the levels 
of ROS in kidney homogenates isolated from α-amanitin 
(1 mg/kg i.p.)-treated mice were found to be increased 
(Zheleva 2013), whereas in vitro, the formation of phe-
noxyl radical after oxidation of α-amanitin was demon-
strated (Zheleva 2013). Although NF-κB pro-inflammatory 
activity is often associated with oxidative stress, in the pre-
sent study, polymyxin B was able to abrogate α-amanitin-
induced protein carbonylation and not NF-κB activation, 
suggesting that the mechanisms involved are dissimilar.
The hindrance of α-amanitin overall toxicity by poly-
myxin B was established by a 30-day survival study. The 
administration of polymyxin B at 4, 8, and 12 h post-
α-amanitin resulted in a 50 % of survival rate, whereas 
all α-amanitin-treated animals died within 5 days. In this 
experimental approach, polymyxin B was administered 4 h 
after α-amanitin exposure, seeking a more realistic treat-
ment approach, since hospitalization after A. phalloides 
human poisoning usually occurs only hours after ingestion. 
Importantly, the concomitant administration of polymyxin 
B and α-amanitin resulted in 100 % survival until the 30th 
day post-exposure, confirming the antidote efficacy.
Taken together, the in silico and the in vivo data obtained 
in the present study demonstrated that polymyxin B acts 
on RNAP II and prevents α-amanitin toxicity. The use of 
polymyxin B in human mushroom poisonings will be the 
main goal to prove the validity of the present work. Clinical 
assays in intoxicated humans are feasible with polymyxin 
B since the doses used in this preclinical study are consid-
ered safe (Zavascki et al. 2007), when allometric scaling is 
applied. The three doses of 2.5 mg/kg of polymyxin B in 
mice sum up to approximately 1 mg/kg in humans, accord-
ing to the allometric scaling (Beck et al. 2014). This poly-
myxin B dose is below the recommended dose of intrave-
nous polymyxin B for the treatment of infections caused 
by Pseudomonas aeruginosa in patients with normal renal 
function (Zavascki et al. 2007). The data presented herein 
suggest that polymyxin B may be used as a novel pharma-
cological approach to the treatment of A. phalloides poi-
soning. Thus, once its antidotal efficacy in humans is fully 
demonstrated, its rapid introduction in the therapeutic anti-
dotal protocol will be of the outmost importance to increase 
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the patient’s survival rate of the putative fatal A. phalloides 
intoxication. For ethical reasons, however, polymyxin B 
should be added to the ongoing therapeutic protocol to 
improve A. phalloides survival and not replace it as to guar-
antee the maximal efficacy of the clinical pharmacological 
weapons available at this point.
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